A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO + VEN) ± azacitidine (AZA; IVO + VEN + AZA) were evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n = 31). Most (91%) advers...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Lachowiez, CA, Loghavi, S, Zeng, Z, Tanaka, T, Kim, YJ, Uryu, H, Turkalj, S, Jakobsen, NA, Luskin, MR, Duose, DY, Tidwell, RSS, Short, NJ, Borthakur, G, Kadia, TM, Masarova, L, Tippett, GD, Bose, P, Jabbour, EJ, Ravandi, F, Daver, NG, Garcia-Manero, G, Kantarjian, H, Garcia, JS, Vyas, P, Takahashi, K, Konopleva, M, DiNardo, CD
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	American Association for Cancer Research 2023

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

समान संसाधन